519 results on '"Lutz, Patrick"'
Search Results
102. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30‐year nationwide cohort of 1478 patients under 18 years of age
103. Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia
104. Greenfeedr: an R-package for processing and reporting GreenFeed data
105. Processing Core/Alloy/Shell Nanoparticles: Tunable Optical Properties and Evidence for Self-Limiting Alloy Growth
106. PRESERVING Hydantoin TECHNOLOGY : Safe, effective, and broad-spectrum describe hydantoin preservatives for today's cosmetic products
107. t(12;21)/ETV6 -RUNX1 Confers a Specific Pattern of In Vivo Sensitivity to Treatments in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Trials 58881 and 58951 of the EORTC Children Leukemia Group
108. Hematopoietic Stem Cell Transplantation from HLA Identical Sibling Forsickle Cell Disease an International Survey on Behalf of Eurocord-Monacord, EBMT Paediatric Disease Working Party and CIBMTR
109. Impact of therapy in a cohort of unselected children with Down Syndrome-associated Acute Lymphoblastic Leukaemia
110. Evans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort
111. Risk Factors and Outcomes According to Age at Transplant with an HLA Identical Sibling for Sickle Cell Disease
112. Heterostructured Au/Pd–M (M = Au, Pd, Pt) nanoparticles with compartmentalized composition, morphology, and electrocatalytic activity
113. The transformation of α-Fe nanoparticles into multi-domain FeNi–M3O4(M = Fe, Ni) heterostructures by galvanic exchange
114. Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial.
115. Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French severe congenital neutropenia registry
116. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival
117. Imatinib Has a Negative Impact On Growth In Children With Previously Untreated Chronic Myeloid Leukaemia (CML) In Early Chronic Phase (CP): Results Of The French National Study
118. Hematopoietic Stem Cell Transplantation In Relapsed ALK + Anaplastic Large Cell Lymphoma Of Children and adolescent : A Study On Behalf Of The Sfce and SFGM-TC
119. Sickle Cell Anemia and HSCT: Relation Between ATG, Chimerism, Gvhd and Outcome In Myeloablative Genoidentical Transplants For The SFGM-TC
120. Molecular Responses At 3 Months Are Associated With a Better Subsequent Molecular response and Outcome In Children and Adolescents With CML In Chronic Phase: Results Of a Retrospective Analysis From The French Glivec Phase 4 Study
121. Outcomes After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) In 163 Pediatric Patients (<18 years old): A Retrospective Study On Behalf Of The SFGM-TC
122. Growth Characteristics and Optical Properties of Core/Alloy Nanoparticles Fabricated via the Layer-by-Layer Hydrothermal Route
123. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Juvenile Myelomonocytic Leukemia (JMML) in France: A Retrospective Study of Société Française De Greffe De Moelle Et De Thérapie Cellulaire
124. Low CNS Relapse Incidence without Radiotherapy and Improvement of Outcome: Results of Subsequent EORTC-CLG 58881 and 58951 Trials in Pediatric T-Cell Acute Lymphoblastic Leukemia (ALL)
125. Prolonged E. Coli Asparaginase Therapy Does Not Improve Significantly the Outcome for Children with Low and Average Risk Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL): Final Report of the EORTC-CLG Randomized Phase III Trial 58951
126. Comparison of the dosimetries of 3-dimensions Radiotherapy (3D-RT) with linear accelerator and intensity modulated radiotherapy (IMRT) with helical tomotherapy in children irradiated for neuroblastoma
127. Singlet oxygen induced advanced glycation end-product photobleaching of in vivo human fingertip autofluorescence
128. Exploiting core–shell and core–alloy interfaces for asymmetric growth of nanoparticles
129. Similar Efficacy and Toxicity Profile for Idarubicine and Mitoxantrone in Induction and Intensification Treatment of Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS): Long-Term Results of the EORTC-CLG Randomized Phase III Trial 58921
130. In Childhood B-Lineage Acute Lymphoblastic Leukemia (B-ALL) with Hyperdiploidy >50 Chromosomes, Patients with 58 to 66 Chromosomes Have 99% EFS At 6-Year Follow-up: Results of the EORTC CLG 58951 Trial
131. The Prognosis of Children Acute Lymphoblastic Leukemia (ALL) with Minimal Residual Disease (MRD) ≥10-2 After Induction (TP1) Depends on the Prephase Response and on the Level of the MRD After Consolidation (TP2): Results of the 58951EORTC Trial
132. Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial
133. Processing Core/Alloy/Shell Nanoparticles: Tunable Optical Properties and Evidence for Self-Limiting Alloy Growth
134. Related Myeloablative Stem Cell Transplantation (SCT) to Cure Sickle Cell Anemia (SCA): Update of French Results
135. Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Multicenter Open French Study In High-Risk pediatrics
136. Metabolomic pattern of childhood neuroblastoma obtained by 1H-high-resolution magic angle spinning (HRMAS) NMR spectroscopy
137. Abstract 5264: Are the methylation of MGMT (O6-methylguanine-DNA methyltransferase) and the DNA mismatch repair (MMR) mechanism frequently involved in pediatric cancers?
138. Rituximab in the management of chronic immune thrombocytopenic purpura: What is its place?
139. Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric Oncology
140. Confirmation of a novel recurrent association: BCR-ABL t(9;22) and t(19;21)
141. Dexamethasone(DEX)(6mg/sm/d) and Prednisolone(PRED)(60mg/sm/d) in Induction Therapy of Childhood ALL Are Equally Effective: Results of the 2nd Interim Analysis of EORTC Trial 58951
142. Improved Outcome with Pulses of Vincristine and Steroids in Continuation Therapy of Children with Average Risk Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL): Final Report of the EORTC Randomized Phase III Trial 58951
143. Prognostic Significance of Central Nervous System (CNS) Status of Children with Acute Lymphoblastic Leukemia (ALL) Treated without Cranial Irradiation: Results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group Study 58951
144. Are There Specific Markers in Allografted Patients Blood Predicting GvHD?
145. Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial
146. Laparoscopic Partial Splenectomy: Indications and results of a multicenter retrospective study
147. Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials.
148. KIT gene in pediatric osteosarcomas: Could it be a new therapeutic target?
149. The transformation of α-Fe nanoparticles into multi-domain FeNi–M3O4 (M = Fe, Ni) heterostructures by galvanic exchange.
150. Prognostic Significance of Blasts with/without Pleiocytosis in the Cerebro-Spinal Fluid (CSF) of Children with Acute Lymphoblastic Leukemia (ALL) Treated without Cranial Irradiation: Results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group Study 58881.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.